These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 32243836)

  • 1. Targeted Metabolic Reprogramming to Improve the Efficacy of Oncolytic Virus Therapy.
    Kennedy BE; Sadek M; Gujar SA
    Mol Ther; 2020 Jun; 28(6):1417-1421. PubMed ID: 32243836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic Viruses: Therapeutics With an Identity Crisis.
    Breitbach CJ; Lichty BD; Bell JC
    EBioMedicine; 2016 Jul; 9():31-36. PubMed ID: 27407036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinguishing the pros and cons of metabolic reprogramming in oncolytic virus immunotherapy.
    Wang S; Wei J
    Int J Cancer; 2022 Nov; 151(10):1654-1662. PubMed ID: 35633046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-modal Potentiation of Oncolytic Virotherapy by Vanadium Compounds.
    Selman M; Rousso C; Bergeron A; Son HH; Krishnan R; El-Sayes NA; Varette O; Chen A; Le Boeuf F; Tzelepis F; Bell JC; Crans DC; Diallo JS
    Mol Ther; 2018 Jan; 26(1):56-69. PubMed ID: 29175158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-36γ-armed oncolytic virus exerts superior efficacy through induction of potent adaptive antitumor immunity.
    Yang M; Giehl E; Feng C; Feist M; Chen H; Dai E; Liu Z; Ma C; Ravindranathan R; Bartlett DL; Lu B; Guo ZS
    Cancer Immunol Immunother; 2021 Sep; 70(9):2467-2481. PubMed ID: 33538860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy.
    Ricca JM; Oseledchyk A; Walther T; Liu C; Mangarin L; Merghoub T; Wolchok JD; Zamarin D
    Mol Ther; 2018 Apr; 26(4):1008-1019. PubMed ID: 29478729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Pyruvate Dehydrogenase Kinase Enhances the Antitumor Efficacy of Oncolytic Reovirus.
    Kennedy BE; Murphy JP; Clements DR; Konda P; Holay N; Kim Y; Pathak GP; Giacomantonio MA; Hiani YE; Gujar S
    Cancer Res; 2019 Aug; 79(15):3824-3836. PubMed ID: 31088833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunomodulation in Oncolytic Measles Virotherapy.
    Dietz L; Engeland CE
    Methods Mol Biol; 2020; 2058():111-126. PubMed ID: 31486034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tuning cellular metabolism for cancer virotherapy.
    Xiong D; Wang Q; Wang WM; Sun ZJ
    Cancer Lett; 2024 Jun; 592():216924. PubMed ID: 38718886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas.
    Zeng J; Li X; Sander M; Zhang H; Yan G; Lin Y
    Front Immunol; 2021; 12():721830. PubMed ID: 34675919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic interaction between oncolytic viruses augments tumor killing.
    Le Boeuf F; Diallo JS; McCart JA; Thorne S; Falls T; Stanford M; Kanji F; Auer R; Brown CW; Lichty BD; Parato K; Atkins H; Kirn D; Bell JC
    Mol Ther; 2010 May; 18(5):888-95. PubMed ID: 20234341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Functional Assay to Determine the Capacity of Oncolytic Viruses to Induce Immunogenic Tumor Cell Death.
    Delaunay T; Achard C; Grégoire M; Tangy F; Boisgerault N; Fonteneau JF
    Methods Mol Biol; 2020; 2058():127-132. PubMed ID: 31486035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic virus therapy: A new era of cancer treatment at dawn.
    Fukuhara H; Ino Y; Todo T
    Cancer Sci; 2016 Oct; 107(10):1373-1379. PubMed ID: 27486853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in oncolytic virus-based cancer therapy.
    Fu LQ; Wang SB; Cai MH; Wang XJ; Chen JY; Tong XM; Chen XY; Mou XZ
    Virus Res; 2019 Sep; 270():197675. PubMed ID: 31351879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
    Marchini A; Scott EM; Rommelaere J
    Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Updates to the antitumor mechanism of oncolytic virus.
    Bai Y; Hui P; Du X; Su X
    Thorac Cancer; 2019 May; 10(5):1031-1035. PubMed ID: 30900824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of oncolytic virotherapy: from genetic modification to combination therapy.
    Lan Q; Xia S; Wang Q; Xu W; Huang H; Jiang S; Lu L
    Front Med; 2020 Apr; 14(2):160-184. PubMed ID: 32146606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies.
    Gujar S; Pol JG; Kim Y; Lee PW; Kroemer G
    Trends Immunol; 2018 Mar; 39(3):209-221. PubMed ID: 29275092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic viruses and immunity.
    Chaurasiya S; Chen NG; Fong Y
    Curr Opin Immunol; 2018 Apr; 51():83-90. PubMed ID: 29550660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic viruses-immunotherapeutics on the rise.
    Keller BA; Bell JC
    J Mol Med (Berl); 2016 Sep; 94(9):979-91. PubMed ID: 27492706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.